5-Year Outcomes Following Catheter Ablation for Paroxysmal Atrial Fibrillation: A Propensity Matched Analysis of 51,182 Patients from a Real World Cohort.

IF 4.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Ahmed Maraey, Dharmindra Dulal, Ahmed Elzanaty, Mahmoud Khalil, Hadeer Elsharnoby, Mohammad Alqadi, Omar Kahaly, Abhishek Maan, Paul Chacko
{"title":"5-Year Outcomes Following Catheter Ablation for Paroxysmal Atrial Fibrillation: A Propensity Matched Analysis of 51,182 Patients from a Real World Cohort.","authors":"Ahmed Maraey, Dharmindra Dulal, Ahmed Elzanaty, Mahmoud Khalil, Hadeer Elsharnoby, Mohammad Alqadi, Omar Kahaly, Abhishek Maan, Paul Chacko","doi":"10.1093/ehjqcco/qcaf020","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Atrial fibrillation (AF) poses significant risks of stroke and mortality. Catheter ablation (CA) has emerged as a superior rhythm control strategy compared to medical therapy, but its long-term benefits in AF, in ischemic stroke prevention, remain underexplored.</p><p><strong>Methods: </strong>This observational study analyzed data from the TriNetX Research Network, encompassing over 115 million patients. Adults diagnosed with paroxysmal atrial fibrillation (PAF) between 2012 and 2019 were stratified into CA and non-CA groups. Propensity score matching (PSM) accounted for baseline differences in demographics, comorbidities, and medication use. The primary outcome was ischemic stroke rates at five years, with and without prior ischemic stroke. Secondary outcomes included all-cause mortality. Kaplan-Meier survival analysis and Cox proportional hazards regression were used to estimate adjusted hazard ratios (HRs).</p><p><strong>Results: </strong>Among 791,013 patients with PAF, 53,178 (6.7%) underwent CA. Post-PSM, ischemic stroke rates were significantly lower in the CA group (7.96% vs. 9.52%, HR: 0.823, 95% CI: 0.785-0.863, p < 0.0001), even after excluding patients with prior ischemic stroke (de-novo ischemic stroke) (4.70% vs. 6.43% HR: 0.709, 95% CI: 0.665-0.756, p < 0.0001). All-cause mortality was markedly reduced (9.33% vs. 20.68% HR: 0.388, 95% CI: 0.373-0.404, p < 0.0001).</p><p><strong>Conclusion: </strong>This large-scale study demonstrates that in PAF patients CA is associated with lower ischemic stroke rates and all-cause mortality compared to a PSM group without CA. These findings support urgent evaluation of CA in managing PAF and highlight its role in potentially improving survival and reducing stroke risk. Further trials are needed to support these findings.</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":" ","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Heart Journal - Quality of Care and Clinical Outcomes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ehjqcco/qcaf020","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Atrial fibrillation (AF) poses significant risks of stroke and mortality. Catheter ablation (CA) has emerged as a superior rhythm control strategy compared to medical therapy, but its long-term benefits in AF, in ischemic stroke prevention, remain underexplored.

Methods: This observational study analyzed data from the TriNetX Research Network, encompassing over 115 million patients. Adults diagnosed with paroxysmal atrial fibrillation (PAF) between 2012 and 2019 were stratified into CA and non-CA groups. Propensity score matching (PSM) accounted for baseline differences in demographics, comorbidities, and medication use. The primary outcome was ischemic stroke rates at five years, with and without prior ischemic stroke. Secondary outcomes included all-cause mortality. Kaplan-Meier survival analysis and Cox proportional hazards regression were used to estimate adjusted hazard ratios (HRs).

Results: Among 791,013 patients with PAF, 53,178 (6.7%) underwent CA. Post-PSM, ischemic stroke rates were significantly lower in the CA group (7.96% vs. 9.52%, HR: 0.823, 95% CI: 0.785-0.863, p < 0.0001), even after excluding patients with prior ischemic stroke (de-novo ischemic stroke) (4.70% vs. 6.43% HR: 0.709, 95% CI: 0.665-0.756, p < 0.0001). All-cause mortality was markedly reduced (9.33% vs. 20.68% HR: 0.388, 95% CI: 0.373-0.404, p < 0.0001).

Conclusion: This large-scale study demonstrates that in PAF patients CA is associated with lower ischemic stroke rates and all-cause mortality compared to a PSM group without CA. These findings support urgent evaluation of CA in managing PAF and highlight its role in potentially improving survival and reducing stroke risk. Further trials are needed to support these findings.

阵发性心房颤动导管消融后的5年预后:来自真实世界队列的51,182例患者的倾向匹配分析
背景:房颤(AF)具有显著的卒中和死亡风险。与药物治疗相比,导管消融(CA)已成为一种更好的心律控制策略,但其在房颤和缺血性卒中预防中的长期益处仍未得到充分探讨。方法:这项观察性研究分析了来自TriNetX研究网络的数据,包括超过1.15亿患者。2012年至2019年间诊断为阵发性心房颤动(PAF)的成年人被分为房颤组和非房颤组。倾向评分匹配(PSM)解释了人口统计学、合并症和药物使用方面的基线差异。主要结局是5年缺血性卒中发生率,有无缺血性卒中史。次要结局包括全因死亡率。Kaplan-Meier生存分析和Cox比例风险回归用于估计校正风险比(hr)。结果:在791,013例PAF患者中,53,178例(6.7%)接受了CA治疗。psm后,CA组的缺血性卒中发生率显著降低(7.96%比9.52%,HR: 0.823, 95% CI: 0.785-0.863, p < 0.0001),即使排除了既往缺血性卒中患者(去新缺血性卒中)(4.70%比6.43% HR: 0.709, 95% CI: 0.665-0.756, p < 0.0001)。全因死亡率显著降低(9.33% vs. 20.68% HR: 0.388, 95% CI: 0.373-0.404, p < 0.0001)。结论:这项大规模研究表明,与没有CA的PSM组相比,PAF患者CA与更低的缺血性卒中发生率和全因死亡率相关。这些发现支持对CA在PAF治疗中的紧急评估,并强调其在改善生存和降低卒中风险方面的潜在作用。需要进一步的试验来支持这些发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
9.40
自引率
3.80%
发文量
76
期刊介绍: European Heart Journal - Quality of Care & Clinical Outcomes is an English language, peer-reviewed journal dedicated to publishing cardiovascular outcomes research. It serves as an official journal of the European Society of Cardiology and maintains a close alliance with the European Heart Health Institute. The journal disseminates original research and topical reviews contributed by health scientists globally, with a focus on the quality of care and its impact on cardiovascular outcomes at the hospital, national, and international levels. It provides a platform for presenting the most outstanding cardiovascular outcomes research to influence cardiovascular public health policy on a global scale. Additionally, the journal aims to motivate young investigators and foster the growth of the outcomes research community.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信